This review continues a general presentation of the metabolism of drugs and other xenobiotics started in a recent issue of Chemistry & Biodiversity. This Part 2 presents the numerous oxidoreductases involved, their nomenclature, relevant biochemical properties, catalytic mechanisms, and the very diverse reactions they catalyze. Many medicinally, environmentally, and toxicologically relevant examples are presented and discussed. Cytochromes P450 occupy a majority of the pages of Part 2, but a large number of relevant oxidoreductases are also considered, e.g., flavin-containing monooxygenases, amine oxidases, molybdenum hydroxylases, peroxidases, and the innumerable dehydrogenases/reductases.

References

1 B. Testa, S. D. Krämer, ‘The Biochemistry of Drug Metabolism – An Introduction. Part 1: Principles and Overview’, Chem. Biodiv. 2006, 3, 1053–1101.
Google Scholar
2 S. Rendic, F. J. Di Carlo, ‘ Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors’, Drug Metab. Rev. 1997, 29, 413–580;
Google Scholar
S. Rendic, ‘Summary of information on human CYP enzymes: Human P450 metabolism data’, Drug Metab. Rev. 2002, 34, 83–448.
Google Scholar
3 O. Pelkonen, ‘ Human CYPs: in vivo and clinical aspects’, Drug Metab. Rev. 2002, 34, 37–46.
Google Scholar
4 B. Testa, ‘The Metabolism of Drugs and Other Xenobiotics – Biochemistry of Redox Reactions’, Academic Press, London, 1995.
Google Scholar
5 ‘Cytochrome P450. Structure, Mechanism, and Biochemistry’, 2nd edn., Ed. P. R. Ortiz de Montellano, Plenum Press, New York, 1996.
Google Scholar
6 ‘ Handbook of Drug Metabolism’, Ed. T. F. Woolf, Dekker, New York, 1999.
Google Scholar
7 ‘Enzyme Systems that Metabolise Drugs and Other Xenobiotics’, Ed. C. Ioannides, Wiley, Chichester, 2002.
Google Scholar
8 ‘Drug–Drug Interactions’, Ed. A. D. Rodrigues, Dekker, New York, 2002.
Google Scholar
9 B. Testa, W. Soine, ‘Principles of drug metabolism’, in ‘Burger's Medicinal Chemistry and Drug Discovery’, 6th edn., Ed. D. J. Abraham, Wiley-Interscience, Hoboken, 2003, Vol. 2, p. 431–498.
Google Scholar
10 ‘Cytochrome P450 Protocols’, Eds. I. R. Phillips, E. A. Shephard, Humana Press, Totowa, 2006.
Google Scholar
11 Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB), ‘Enzyme Nomenclature’, www.chem.qmul.ac.uk/iubmb/enzyme.
Google Scholar
12 F. J. Gonzalez, ‘Molecular genetics of the P-450 superfamily’, Pharmacol. Ther. 1990, 45, 1–38.
Google Scholar
13 D. R. Nelson, D. C. Zeldin, S. M. G. Hoffman, L. J. Maltais, H. M. Wain, D. W. Nebert, ‘Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative splice variants’, Pharmacogenetics 2004, 14, 1–18.
Google Scholar
14a D. R. Nelson, ‘Cytochrome P450 homepage’, http://drnelson.utmem.edu/CytochromeP450.html;
Google Scholar
14b http://drnelson.utmem.edu/Nomenclature.html;
Google Scholar
14c http://drnelson.utmem.edu/hum.html;
Google Scholar
14d http://drnelson.utmem.edu/P450lect.html;
Google Scholar
14e http://drnelson.utmem.edu/P450trees.html.
Google Scholar
15 ‘Directory of P450-containing Systems’, http://www.icgeb.org/~p450srv/.
Google Scholar
16 ‘Brenda: The Comprehensive Enzyme Information System’, www.brenda.uni-koeln.de; ‘ExPASy Proteomics Server’, www.expasy.org.
Google Scholar
17 T. A. Holton, F. Brugliera, D. R. Lester, Y. Tanaka, C. D. Hyland, J. G. T. Menting, C. Y. Lu, E. Fracy, T. W. Stevenson, E. C. Cornish, ‘Cloning and expression of cytochrome P450 genes controlling flower colour’, Nature 1993, 366, 276–279.
Google Scholar
18 W. Y. Precious, J. Barrett, ‘Xenobiotic metabolism in helminths’, Parasitol. Today 1989, 5, 156–160.
Google Scholar
19 X. Ding, L. S. Kaminsky, ‘ Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts’, Annu. Rev. Pharmacol. Toxicol. 2003, 43, 149–173.
Google Scholar
20 A. E. Cribb, M. Peyron, S. Muruganandan, L. Schneider, ‘The endoplasmic reticulum in xenobiotic toxicity’, Drug Metab. Rev. 2005, 37, 405–442.
Google Scholar
21 I. Hanukoglu, ‘Antioxidant protective mechanisms against reactive oxygen species (ROS) generated by mitochondrial P450 systems in steroidogenic cells’, Drug Metab. Rev. 2006, 38, 171–196.
Google Scholar
22 D. R. Nelson, H. W. Strobel, ‘On the membrane topology of vertebrate cytochrome P-450 proteins’, J. Biol. Chem. 1988, 263, 6038–6050.
Google Scholar
23 R. J. Edwards, B. P. Murray, A. M. Singleton, A. R. Boobis, ‘Orientation of cytochromes P450 in the endoplasmic reticulum’, Biochemistry 1991, 30, 71–76.
Google Scholar
24 F. Centero, C. Gutiérrez-Merino, ‘Location of functional centers in the microsomal cytochrome P450 system’, Biochemistry 1992, 31, 8473–8481.
Google Scholar
25 B. S. Masters, C. C. Marohnic, ‘Cytochromes P450 – a family of proteins and scientists – understanding their relationships’, Drug Metab. Rev. 2006, 38, 209–225.
Google Scholar
26a P. A. Williams, J. Cosme, A. Ward, H. C. Angove, D. M. Vinkovic, H. Jhoti, ‘Crystal structure of human cytochrome P450 2C9 with bound warfarin’, Nature 2003, 424, 464–468;
Google Scholar
26b P. A. Williams, J. Cosme, D. M. Vinkovic, A. Ward, H. C. Angove, P. J. Day, C. Vonrhein, I. J. Tickle, H. Jhoti, ‘Crystal structure of human cytochrome P450 3A4 bound to metarypone and progesterone’, Science 2004, 305, 683–686.
Google Scholar
27 F. J. Gonzalez, D. W. Nebert, ‘Evolution of the P450 gene superfamily: animal-plant ‘warfare’, molecular drive and human genetic differences in drug oxidation', Trends Genet. 1990, 6, 182–186;
Google Scholar
A. K. Daly, J. Brockmöller, F. Broly, M. Eichelbaum, W. E. Evans, F. J. Gonzalez, J. D. Huang, J. R. Idle, M. Ingelman-Sundberg, T. Ishizaki, E. Jacqz-Aigrain, U. A. Meyer, D. W. Nebert, V. M. Steen, C. R. Wolf, U. M. Zanger, ‘Nomenclature for human CYP2D6 alleles’, Pharmacogenetics 1996, 6, 193–201; homepage of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee, www.cypalleles.ki.se.
Google Scholar
28 B. Oesch-Bartlomowicz, F. Oesch, ‘Mechanisms of toxification and detoxification that challenge drug candidates and drugs’, in ‘ADME-Tox Approaches’, Eds. B. Testa, H. van de Waterbeemd, Vol. 5 in ‘Comprehensive Medicinal Chemistry’, 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, 2007, p. 193–214.
Google Scholar
29 M. Ingelman-Sundberg, ‘Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development’, Drug Metab. Dispos. 2001, 29, 570–573.
Google Scholar
30 H. Reiser, ‘Pharmacogenetics and drug development’, Annu. Rep. Med. Chem. 2005, 40, 414– 427.
Google Scholar
31 R. A. Totah, A. E. Rettie, ‘Principles of drug metabolism 3: Enzymes and tissues’, in ‘ADME-Tox Approaches’, Eds. B. Testa, H. van de Waterbeemd, Vol. 5 in ‘Comprehensive Medicinal Chemistry’, 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, 2007, p. 167–191.
Google Scholar
32 D. A. Smith, M. J. Ackland, B. C. Jones, ‘Properties of cytochrome P450 isoenzymes and their substrates. Part 1: active site characteristics’, Drug Discov. Today 1997, 2, 406–414;
Google Scholar
D. A. Smith, M. J. Ackland, B. C. Jones, ‘Properties of cytochrome P450 isoenzymes and their substrates. Part 2: properties of cytochrome P450 substrates’, Drug Discov. Today 1997, 2, 479–486.
Google Scholar
33 D. A. Smith, S. M. Abel, R. Hyland, B. C. Jones, ‘ Human cytochrome P450s: selectivity and measurement in vivo’, Xenobiotica 1998, 28, 1095–1128.
Google Scholar
34 D. F. V. Lewis, M. Dickins, P. J. Eddershaw, M. H. Tarbit, P. S. Goldfarb, ‘Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries’, Drug Metab. Drug Interact. 1999, 15, 1–49.
Google Scholar
35 D. F. V. Lewis, ‘On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics’, Biochem. Pharmacol. 2000, 60, 293–306.
Google Scholar
36 S. A. Wrighton, E. G. Schuetz, K. E. Thummel, D. D. Shen, K. R. Korzekwa, P. B. Watkins, ‘The human CYP3A subfamily: practical considerations’, Drug Metab. Rev. 2000, 32, 339–361.
Google Scholar
37 W. R. Scheidt, C. A. Reed, ‘Spin-state/stereochemical relationships in iron porphyrins: implications for the hemoproteins’, Chem. Rev. 1981, 81, 543–555.
Google Scholar
38 D. F. V. Lewis, ‘Physical methods in the study of the active site geometry of cytochromes P-450’, Drug Metab. Rev. 1986, 17, 1–66.
Google Scholar
39 W. F. Trager, ‘The postenzymatic chemistry of activated oxygen’, Drug Metab. Rev. 1982, 13, 51– 69.
Google Scholar
40 M. J. Coon, A. D. N. Vaz, D. F. McGinnity, H. M. Peng, ‘Multiple activated oxygen species in P450 catalysis. Contributions to specificity in drug metabolism’, Drug Metab. Dispos. 1998, 26, 1190–1193.
Google Scholar
41 T. M. Makris, R. Davydov, I. G. Denisov, B. M. Hoffman, S. G. Sligar, ‘Mechanistic enzymology of oxygen activation by the cytochromes P450’, Drug Metab. Rev. 2002, 34, 691–708.
Google Scholar
42 A. L. Shen, M. J. Christensen, C. B. Kasper, ‘NADPH-Cytochrome P450 oxidoreductase. The role of cysteine 566 in catalysis and cofactor binding’, J. Biol. Chem. 1991, 266, 19976–19980.
Google Scholar
43 K. Shirabe, T. Yubisui, T. Nishino, M. Takeshita, ‘Role of cysteine residues in human NADH-cytochrome b5 reductase studied by site-directed mutagenesis’, J. Biol. Chem. 1991, 266, 7531–7536.
Google Scholar
44 D. N. Li, M. P. Pritchard, S. T. Hanlon, B. Burchell, C. R. Wolf, T. Friedberg, ‘Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism’, J. Pharmacol. Exp. Ther. 1999, 289, 661–667.
Google Scholar
45 C. R. Nishida, G. Knudsen, W. Straub, P. R. Ortiz de Montellano, ‘Electron supply and catalytic oxidation of nitrogen by cytochrome P450 and nitric oxide synthase’, Drug Metab. Rev. 2002, 34, 479–501.
Google Scholar
46 J. R. Kurian, S. U. Bajad, J. L. Miller, N. A. Chin, L. A. Trepanier, ‘NADH cytochrome b₅ reductase and cytochrome b₅ catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans’, J. Pharmacol. Exp. Ther. 2004, 311, 1171–1178.
Google Scholar
47 P. R. Ortiz de Montellano, ‘Cytochrome P-450 catalysis: radical intermediates and dehydrogenation reaction’, Trends Pharmacol. Sci. 1989, 10, 354–359.
Google Scholar
48 L. Koymans, G. M. Donné-Op den Kelder, J. M. te Koppele, N. P. E. Vermeulen, ‘Cytochromes P450: Their active-site structure and mechanism of oxidation’, Drug Metab. Rev. 1993, 25, 325–387.
Google Scholar
49 J. Everse, ‘The structure of heme proteins compounds I and II: some misconceptions’, Free Radical Biol. Med. 1998, 24, 1338–1346.
Google Scholar
50 F. P. Guengerich, ‘Cytochrome P450 3A4: Regulation and role in drug metabolism’, Annu. Rev. Pharmacol. Toxicol. 1999, 39, 1–17.
Google Scholar
51 I. Schlichting, J. Berendzen, K. Chu, A. M. Stock, S. A. Maves, D. E. Benson, R. M. Sweet, D. Ringe, G. A. Petsko, S. G. Sligar, ‘The catalytic pathway of cytochrome P450 cam at atomic resolution’, Science 2000, 287, 1615–1622.
Google Scholar
52 F. P. Guengerich, ‘Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity’, Chem. Res. Toxicol. 2001, 14, 611–650.
Google Scholar
53 M. T. Green, J. H. Dawson, H. B. Gray, ‘Oxoiron(IV) in chloroperoxidase compound II is basic: Implications for P450 chemistry’, Science 2004, 304, 1653–1656.
Google Scholar
54 W. F. Trager, ‘Principles of drug metabolism 1: Redox reactions’, in ‘ADME-Tox Approaches’, Eds. B. Testa, H. van de Waterbeemd, Vol. 5 in ‘Comprehensive Medicinal Chemistry’, 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, 2007, p. 87–132.
Google Scholar
55 D. M. Ziegler, ‘Flavin-containing monooxygenases: catalytic mechanism and substrate specificities’, Drug Metab. Rev. 1988, 19, 1–32.
Google Scholar
56 J. R. Cashman, ‘Structural and catalytic properties of the mammalian flavin-containing monooxygenases’, Chem. Res. Toxicol. 1995, 8, 165–181.
Google Scholar
57 I. R. Phillips, C. T. Dolphin, P. Clair, M. R. Hadley, A. J. Hutt, R. R. McCombie, R. L. Smith, E. A. Shephard, ‘The molecular biology of flavin-containing monooxygenases of man’, Chem.-Biol. Interact. 1995, 96, 17–32.
Google Scholar
58 A. A. Elfarra, ‘Potential role of the flavin-containing monooxygenases in the metabolism of endogenous compounds’, Chem.-Biol. Interact. 1995, 96, 47–55.
Google Scholar
59 L. L. Poulsen, D. M. Ziegler, ‘Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity’, Chem.-Biol. Interact. 1995, 96, 57–73.
Google Scholar
60 J. R. Cashman, ‘ Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism’, Curr. Drug Metab. 2000, 1, 181–191.
Google Scholar
61 D. M. Ziegler, ‘An overview of the mechanism, substrate specificities, and structure of FMOs’, Drug Metab. Rev. 2002, 34, 503–511.
Google Scholar
62 J. R. Cashman, ‘The role of flavin-containing monooxygenases in drug metabolism and development’, Curr. Opin. Drug Discov. Dev. 2003, 6, 486–493.
Google Scholar
63 J. R. Cashman, ‘The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development’, Drug Discov. Today 2004, 9, 574–581.
Google Scholar
64 S. K. Krueger, D. E. Williams, ‘Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism’, Pharmacol. Ther. 2005, 106, 357–387.
Google Scholar
65 J. R. Cashman, ‘Some distinctions between flavin-containing and cytochrome P450 monooxygenases’, Biochem. Biophys. Res. Commun. 2005, 338, 599–604; J. R. Cashman, J. Zhang, ‘ Human flavin-containing monooxygenases’, Annu. Rev. Pharmacol. Toxicol. 2006, 46, 65–100.
Google Scholar
66 R. N. Hines, K. A. Hopp, J. Franco, K. Saeian, F. P. Begun, ‘Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase’, Mol. Pharmacol. 2002, 62, 320–325.
Google Scholar
67 S. G. Sligar, M. H. Gelb, D. C. Heimbrook, ‘Bio-organic chemistry and cytochrome P450-dependent catalysis’, Xenobiotica 1984, 14, 63–86.
Google Scholar
68 F. P. Guengerich, T. L. Macdonald, ‘Chemical mechanisms of catalysis by cytochromes P-450: a unified view’, Acc. Chem. Res. 1984, 17, 9–16.
Google Scholar
69 J. T. Groves, ‘Key elements of the chemistry of cytochrome P-450. The oxygen rebound mechanism’, J. Chem. Educ. 1985, 62, 928–931.
Google Scholar
70 R. E. White, J. P. Miller, L. V. Favreau, A. Bhattacharyya, ‘Stereochemical dynamics of aliphatic hydroxylation by cytochrome P-450’, J. Am. Chem. Soc. 1986, 108, 6024–6031.
Google Scholar
71 J. K. Atkinson, K. U. Ingold, ‘Cytochrome P450 hydroxylation of hydrocarbons: variation in the rate of oxygen rebound using cyclopropyl radical clocks including two new ultrafast probes’, Biochemistry 1993, 32, 9209–9214.
Google Scholar
72 R. E. White, M. B. McCarthy, K. D. Egeberg, S. G. Sligar, ‘Regioselectivity in the cytochrome P-450: control by protein constraints and by chemical reactivity’, Arch. Biochem. Biophys. 1984, 228, 493–502.
Google Scholar
73 L. Perbellini, F. Brugnone, V. Cocheo, E. De Rosa, G. B. Bartolucci, ‘Identification of the n-heptane metabolites in rat and human urine’, Arch. Toxicol. 1986, 58, 229–234.
Google Scholar
74 T. Ishida, ‘Biotransformation of terpinoids by mammals, microorganisms, and plant-cultured cells’, Chem. Biodiv. 2005, 2, 569–590.
Google Scholar
75 M. Miyazawa, M. Shinto, T. Shimada, ‘Sex differences in the metabolism of (+)- and (−)-limonene enantiomers to carveol and perillyl alcohol derivatives by cytochrome P450 enzymes in rat liver microsomes’, Chem. Res. Toxicol. 2002, 15, 15–20.
Google Scholar
76 R. E. McMahon, H. R. Sullivan, J. C. Craig, W. E. Pereira Jr., ‘The microsomal oxygenation of ethylbenzene: isotopic, stereochemical, and induction studies’, Arch. Biochem. Biophys. 1969, 132, 575–577.
Google Scholar
77 L. Drummond, J. Caldwell, H. K. Wilson, ‘The metabolism of ethylbenzene and styrene to mandelic acid: stereochemical considerations’, Xenobiotica 1989, 19, 199–207.
Google Scholar
78 S. K. Paulson, J. Y. Zhang, A. P. Breau, J. D. Hribar, N. W. K. Liu, S. M. Jessen, Y. M. Lawal, J. N. Cogburn, C. J. Gresk, C. S. Markos, T. J. Maziasz, G. L. Schoenhard, E. G. Burton, ‘Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats’, Drug Metab. Dispos. 2000, 28, 514–521.
Google Scholar
79 S. K. Paulson, J. D. Hribar, N. W. K. Liu, E. Hajdu, R. H. Bible Jr., A. Piergies, A. Karim, ‘Metabolism and excretion of [¹⁴C]celecoxib in healthy male volunteers’, Drug Metab. Dispos. 2000, 28, 308–314.
Google Scholar
80 B. Eiermann, P. O. Edlund, A. Tjernberg, P. Dalén, M. L. Dahl, L. Bertilsson, ‘1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans’, Drug Metab. Dispos. 1998, 26, 1096–1101.
Google Scholar
81 I. Midgley, K. Fitzpatrick, S. J. Wright, B. A. John, A. J. Peard, R. M. Major, J. D. Major, J. D. Holding, A. McBurney, R. Anacardio, R. Novellini, M. P. Ferrari, ‘Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog’, Xenobiotica 2006, 36, 419–440.
Google Scholar
82 M. M. Callahan, R. S. Robertson, M. J. Arnaud, A. R. Branfman, M. F. McComish, D. W. Yesair, ‘ Human metabolism of [1-methyl-¹⁴C]- and [2-¹⁴C]caffeine after oral administration’, Drug Metab. Dispos. 1982, 10, 417–423.
Google Scholar
83 F. Berthou, B. Guillois, C. Riche, Y. Dreano, E. Jacqz-Aigrain, P. H. Beaune, ‘Interspecies variations in caffeine metabolism related to cytochrome P4501A’, Xenobiotica 1992, 22, 671–680.
Google Scholar
84 J. O. Miners, D. J. Birkett, ‘The use of caffeine as a metabolic probe for human drug metabolizing enzymes’, Gen. Pharmacol. 1996, 27, 245–249.
Google Scholar
85 G. Ginsberg, D. Hattis, A. Russ, B. Sonawane, ‘Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents’, J. Toxicol. Environ. Health A 2004, 67, 297–329.
Google Scholar
86 A. E. Mutlib, W. L. Nelson, ‘Pathways of gallopamil metabolism. Regiochemistry and enantioselectivity of the N-dealkylation processes’, Drug Metab. Dispos. 1990, 18, 331–337.
Google Scholar
87 A. E. Mutlib, W. L. Nelson, ‘Pathways of gallopamil metabolism. Regiochemistry and enantioselectivity of the O-demethylation processes’, Drug Metab. Dispos. 1990, 18, 309–314.
Google Scholar
88 M. Eichelbaum, M. Ende, G. Remberg, M. Schomerus, H. J. Dengler, ‘The metabolism of DL-[14C]verapamil in man’, Drug Metab. Dispos. 1979, 7, 145–148.
Google Scholar
89 L. Shen, J. F. Fitzloff, C. S. Cook, ‘Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As’, Drug Metab. Dispos. 2004, 32, 186–196.
Google Scholar
90 S. Vickers, S. L. Polsky, ‘The biotransformation of nitrogen-containing xenobiotics to lactams’, Curr. Drug Metab. 2000, 1, 357–389.
Google Scholar
91 J. Hukkanen, P. Jacob III, N. L. Benowitz, ‘Metabolism and disposition of nicotine’, Pharmacol. Rev. 2005, 57, 79–115.
Google Scholar
92 D. Yildiz, ‘Nicotine, its metabolism and an overview of its biological effects’, Toxicon 2004, 43, 619–632.
Google Scholar
93 D. McKillop, A. D. McCormick, G. S. Miles, P. J. Phillips, K. J. Pickup, N. Bushby, M. Hutchison, ‘In vitro metabolism of gefitinib in human liver microsomes’, Xenobiotica 2004, 34, 983–1000.
Google Scholar
94 D. McKillop, A. D. McCormick, A. Millar, G. S. Miles, P. J. Phillips, M. Hutchison, ‘Cytochrome P450-dependent metabolism of gefitinib’, Xenobiotica 2005, 35, 39–50.
Google Scholar
95 H. M. Peng, G. M. Raner, A. D. N. Vaz, M. J. Coon, ‘Oxidative cleavage of esters and amides to carbonyl products by cytochrome P450’, Arch. Biochem. Biophys. 1995, 318, 333–339.
Google Scholar
96 N. Yumibe, K. Huie, K. J. Chen, M. Snow, R. P. Clement, M. N. Cayen, ‘Identification of human liver cytochrome P450 enzymes that metabolize the nonsedative antihistamine loratadine. Formation of descarboxyethoxyloratadine by CYP3A4 and CYP2D6’, Biochem. Pharmacol. 1996, 51, 165–172.
Google Scholar
97 R. Ramanathan, N. Alvarez, A. D. Su, S. Chowdhury, K. Alton, K. Stauber, J. Patrick, ‘Metabolism and excretion of loratadine in male and female mice, rats and monkeys’, Xenobiotica 2005, 35, 155–189.
Google Scholar
98 C. S. Lieber, L. M. DeCarli, ‘ Hepatic microsomal ethanol-oxidizing system’, J. Biol. Chem. 1970, 245, 2505–2512.
Google Scholar
99 H. Asai, S. Imaoka, T. Kuroki, T. Monna, Y. Funae, ‘Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s’, J. Pharmacol. Exp. Ther. 1996, 277, 1004–1009.
Google Scholar
100 T. Matsunaga, N. Kishi, H. Tanaka, K. Watanabe, H. Yoshimura, I. Yamamoto, ‘Major cytochrome P450 enzyme responsible for oxidation of secondary alcohols to the corresponding ketones in mouse hepatic microsomes’, Drug Metab. Dispos. 1998, 26, 1045–1047.
Google Scholar
101 S. Kunitoh, S. Imaoka, T. Hiroi, Y. Yabusaki, T. Monna, Y. Funae, ‘Acetaldehyde as well as ethanol is metabolized by human CYP2E1’, J. Pharmacol. Exp. Ther. 1997, 280, 527–532.
Google Scholar
102 D. K. Spracklin, D. C. Hankins, J. M. Fisher, K. E. Thummel, E. D. Kharasch, ‘Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro’, J. Pharmacol. Exp. Ther. 1997, 281, 400–411.
Google Scholar
103 J. Gut, U. Christen, J. Huwyler, ‘Mechanisms of halothane toxicity: novel insights’, Pharmacol. Ther. 1993, 58, 133–155.
Google Scholar
104 K. J. Garton, P. Yuen, J. Meinwald, K. E. Thummel, E. D. Kharasch, ‘Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1’, Drug Metab. Dispos. 1995, 23, 1426–1430.
Google Scholar
105 J. Halpert, ‘Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol’, Biochem. Pharmacol. 1981, 30, 875–881.
Google Scholar
106 K. Watanabe, S. Narimatsu, I. Yamamoto, H. Yoshimura, ‘ Hepatic microsomal oxygenation of aldehydes to carboxylic acids’, Biochem. Biophys. Res. Commun. 1990, 166, 1308–1312.
Google Scholar
107 K. Watanabe, S. Narimatsu, I. Yamamoto, H. Yoshimura, ‘Oxygenation mechanism of aldehyde to carboxylic acid catalyzed by a cytochrome P450 isozyme’, J. Biol. Chem. 1991, 266, 2709–2711.
Google Scholar
108 R. A. Stearns, P. K. Chakravarty, R. Chen, S. H. Chiu, ‘Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes’, Drug Metab. Dispos. 1995, 23, 207–215.
Google Scholar
109 M. Bartók, K. L. Láng, ‘Oxiranes’, in ‘Small Ring Heterocycles, Part 3’, Ed. A. Hassner, Wiley, New York, 1985, p. 1–196.
Google Scholar
110 C. Chiappe, A. De Rubertis, G. Amato, P. G. Gervasi, ‘Stereochemistry of the biotransformation of 1-hexene and 2-methyl-1-hexene with rat liver microsomes and purified P450s of rats and humans’, Chem. Res. Toxicol. 1998, 11, 1487–1493.
Google Scholar
111 C. Chiappe, A. De Rubertis, M. De Carlo, G. Amato, P. G. Gervasi, ‘Stereochemial aspects in the 4-vinylcyclohexene biotransformation with rat liver microsomes and purified P450s. Monoepoxides and diols’, Chem. Res. Toxicol. 2001, 14, 492–499.
Google Scholar
112 R. E. Miller, F. P. Guengerich, ‘Oxidation of trichloroethylene by liver microsomal cytochrome P-450: evidence for chlorine migration in a transition state not involving trichloroethylene oxide’, Biochemistry 1982, 21, 1090–1097.
Google Scholar
113 K. Lertratanangkoon, M. G. Horning, ‘Metabolism of carbamazepine’, Drug Metab. Rev. 1982, 10, 1–10.
Google Scholar
114 B. Rambeck, T. May, U. Juergens, ‘Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication’, Ther. Drug Monit. 1987, 9, 298–303.
Google Scholar
115 R. E. Pearce, G. R. Vakkalagadda, J. S. Leeder, ‘Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites’, Drug Metab. Dispos. 2002, 30, 1170–1179.
Google Scholar
116 J. Seidegard, J. W. DePierre, ‘Microsomal epoxide hydrolase. Properties, regulation and function’, Biochim. Biophys. Acta 1983, 695, 251–270.
Google Scholar
117 B. Testa, ‘Principles of drug metabolism 2: Hydrolysis and conjugation reactions’, in ‘ADME-Tox Approaches’, Eds. B. Testa, H. van de Waterbeemd, Vol. 5 in ‘Comprehensive Medicinal Chemistry’, 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, 2007, p. 133–166.
Google Scholar
118 R. A. Halpin, A. G. Porras, L. A. Geer, M. R. Davis, D. Cui, G. A. Doss, E. Woolf, D. Musson, C. Matthews, R. Mazenko, J. I. Schwartz, K. C. Lasseter, K. P. Vyas, T. A. Baillie, ‘The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects’, Drug Metab. Dispos. 2002, 30, 684–693.
Google Scholar
119 T. S. Dowers, D. A. Rock, D. A. Rock, B. N. S. Perkins, J. P. Jones, ‘An analysis of the regioselectivity of aromatic hydroxylation and N-oxygenation by cytochrome P450 enzymes’, Drug Metab. Dispos. 2004, 32, 328–332.
Google Scholar
120 D. K. Dalvie, A. S. Katgutkar, S. C. Khojasteh-Bakht, R. S. Obach, J. P. O'Donnell, ‘Biotransformation reactions of five-membered aromatic heterocyclic rings’, Chem. Res. Toxicol. 2002, 15, 269–299.
Google Scholar
121 P. Morgan, J. L. Maggs, P. C. B. Page, B. K. Park, ‘Oxidative dehalogenation of 2-fluoro-17α-ethynylestradiol in vivo. A distal structure-metabolism relationship of 17α-ethynylation’, Biochem. Pharmacol. 1992, 44, 1717–1724.
Google Scholar
122 T. Ohe, T. Mashino, M. Hirobe, ‘Substituent elimination from p-substituted phenols by cytochrome P450. ipso-substitution by the oxygen atom of the active species’, Drug Metab. Dispos. 1997, 25, 116–122.
Google Scholar
123 S. Safe, D. Jones, O. Hutzinger, ‘Metabolism of 4,4’-dihalogenobiphenyls', J. Chem. Soc., Perkin Trans. 1 1976, 357–359.
Google Scholar
124 T. Walle, J. E. Oatis Jr., U. K. Walle, D. R. Knapp, ‘New ring-hydroxylated metabolites of propranolol’, Drug Metab. Dispos. 1982, 10, 122–127.
Google Scholar
125 W. L. Nelson, M. J. Bartels, ‘Stereoselectivity in the aromatic hydroxylation of propranolol in rats’, Drug Metab. Dispos. 1984, 12, 382–384.
Google Scholar
126 W. L. Nelson, M. J. Bartels, P. J. Bednarski, S. Zhang, K. Messick, J. S. Horng, R. R. Ruffolo Jr., ‘The 3,4-catechol derivative of propranolol, a minor dihydroxylated metabolite’, J. Med. Chem. 1984, 27, 857–861.
Google Scholar
127 R. E. Talaat, W. L. Nelson, ‘Regioisomeric aromatic dihydroxylation of propranolol’, Drug Metab. Dispos. 1988, 16, 207–211, 212–216.
Google Scholar
128 S. A. Ward, T. Walle, U. K. Walle, G. R. Wilkinson, R. A. Branch, ‘Propranolol metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities’, Clin. Pharmacol. Ther. 1989, 45, 72–79.
Google Scholar
129 M. J. Fasco, P. P. Dymerski, J. D. Wos, L. S. Kaminsky, ‘A new warfarin metabolite: structure and function’, J. Med. Chem. 1978, 21, 1054–1059.
Google Scholar
130 L. S. Kaminsky, ‘Warfarin as a probe of cytochromes P450 function’, Drug Metab. Rev. 1989, 20, 479–487.
Google Scholar
131 A. E. Rettie, K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, W. F. Trager, ‘ Hydroxylation of warfarin by cDNA-expressed cytochromes P450: A role for P4502C9 in the etiology of (S)-warfarin-drug interactions’, Chem. Res. Toxicol. 1992, 5, 54–59.
Google Scholar
132 Z. Zhang, M. J. Fasco, Z. Huang, F. P. Guengerich, L. S. Kaminsky, ‘ Human cytochromes P4501A1 and P4501A2: R-Warfarin metabolism as a probe’, Drug Metab. Dispos. 1995, 23, 1339–1345.
Google Scholar
133 J. S. Ngui, Q. Chen, M. Shou, R. W. Wang, R. A. Stearns, T. A. Baillie, W. Tang, ‘In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin’, Drug Metab. Dispos. 2001, 29, 877–886.
Google Scholar
134 I. N. H. White, ‘Suicidal destruction of cytochrome P-450 by ethynyl substituted compounds’, Pharm. Res. 1984, 1, 141–148.
Google Scholar
135 S. E. Schmid, W. Y. W. Au, D. E. Hill, F. F. Kadlubar, W. Slikker Jr., ‘Cytochrome P450-dependent oxidation of the 17a-ethynyl group of synthetic steroids’, Drug Metab. Dispos. 1983, 11, 531– 536.
Google Scholar
136 E. S. Roberts, N. E. Hopkins, W. L. Alworth, P. F. Hollenberg, ‘Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: Identification of an active-site peptide’, Chem. Res. Toxicol. 1993, 6, 470–479.
Google Scholar
137 A. Wade, A. M. Symons, L. Martin, D. V. Parke, ‘Metabolic oxidation of the ethynyl group in 4-ethynylbiphenyl’, Biochem. J. 1979, 184, 509–517.
Google Scholar
138 A. Wade, A. M. Symons, L. Martin, D. V. Parke, ‘The metabolic oxidation of the ethynyl group in 4-ethynylbiphenyl in vitro’, Biochem. J. 1980, 188, 867–872.
Google Scholar
139 I. N. H. White, ‘Structure-activity relationships in the destruction of cytochrome P450 mediated by certain ethynyl-substituted compounds in rats’, Biochem. Pharmacol. 1980, 29, 3253–3255.
Google Scholar
140 P. W. Fan, C. Gu, S. A. Marsh, J. C. Stevens, ‘Mechanism-based inactivation of cytochrome P450 2B6 by a novel terminal acetylene inhibitor’, Drug Metab. Dispos. 2003, 31, 28–36.
Google Scholar
141 K. K. Khan, Y. Q. He, M. A. Correia, J. R. Halpert, ‘Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: Selective inactivation of P450 3A4’, Drug Metab. Dispos. 2002, 30, 985–990.
Google Scholar
142 J. W. Gorrod, ‘Differentiation of various types of biological oxidation of nitrogen in organic compounds’, Chem.-Biol. Interact. 1973, 7, 289–303.
Google Scholar
143 D. H. Lang, C. K. Yeung, R. M. Peter, C. Ibarra, R. Gasser, K. Itagaki, R. M. Philpot, A. E. Rettie, ‘Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes’, Biochem. Pharmacol. 1998, 56, 1005–1012.
Google Scholar
144 G. Caron, G. Ermondi, D. Boschi, P. A. Carrupt, R. Fruttero, B. Testa, A. Gasco, ‘Structure–property relations in the basicity and lipophilicity of arylalkylamine oxides’, Helv. Chim. Acta 1999, 82, 1630–1639.
Google Scholar
145 E. M. Hawes, T. J. Jawoeski, K. K. Midha, G. McKay, J. W. Hubbard, E. D. Korchinski, ‘In vivo metabolism of N-oxides’, in ‘N-Oxidation of Drugs: Biochemistry, Pharmacology, Toxicology’, Eds. P. Hlavida, L. A. Damani, Chapman and Hall, London, 1991, p. 263–286.
Google Scholar
146 U. Breyer-Pfaff, ‘The metabolic fate of amitriptyline, nortriptyline and amitryptylinoxide in man’, Drug Metab. Rev. 2004, 36, 723–746.
Google Scholar
147 J. R. Cashman, S. B. Park, C. E. Berkman, L. E. Cashman, ‘Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans’, Chem.-Biol. Interact. 1995, 96, 33–46.
Google Scholar
148 S. Øie, T. W. Guentert, L. Tolentino, G. Hermodsson, ‘Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats’, J. Pharm. Pharmacol. 1992, 44, 413–418.
Google Scholar
149 J. R. Cashman, Y. N. Xiong, L. Xu, A. Janowsky, ‘N-Oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (Form 3): Role in bioactivation and detoxication’, J. Pharmacol. Exp. Ther. 1999, 288, 1251–1260.
Google Scholar
150 J. Lin, C. E. Berkman, J. R. Cashman, ‘N-Oxygenation of primary amines and hydroxylamines and retroreduction of hydroxylamines by adult human liver microsomes and adult human flavin-containing monooxygenase 3’, Chem. Res. Toxicol. 1996, 9, 1183–1193.
Google Scholar
151 J. Lin, J. R. Cashman, ‘N-Oxygenation of phenylethylamine to the trans-oxime by adult human liver flavin-containing monooxygenase and retroreduction of phenylethylamine hydroxylamine by human liver microsomes’, J. Pharmacol. Exp. Ther. 1997, 282, 1269–1279.
Google Scholar
152 K. E. Mc Lane, J. Fisher, K. Ramakrishnan, ‘Reductive drug metabolism’, Drug Metab. Rev. 1983, 14, 741–799.
Google Scholar
153 F. P. Guengerich, R. H. Böcker, ‘Cytochrome P450-catalyzed dehydrogenation of 1,4-dihydropyridines’, J. Biol. Chem. 1988, 263, 8168–8175.
Google Scholar
154 F. P. Guengerich, W. R. Brian, M. Iwasaki, M. A. Sari, C. Bäärnhielm, P. Berntsson, ‘Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450 IIIA4’, J. Med. Chem. 1991, 34, 1838–1844.
Google Scholar
155 F. P. Guengerich, ‘N-Hydroxylarylamines’, Drug Metab. Rev. 2002, 34, 607–623;
Google Scholar
D. Kim, F. P. Guengerich, ‘Cytochrome P450 activation of arylamines and heterocyclic amines’, Annu. Rev. Pharmacol. Toxicol. 2005, 45, 27–49.
Google Scholar
156 G. P. Ford, J. W. Thompson, ‘Regiochemistry of nucleophilic attack by the guanine 2-amino group at the ring positions of nitrenium ions derived from carcinogenic polycyclic arylamines and nitroarenes: Molecular orbital calculations and simple models’, Chem. Res. Toxicol. 1999, 12, 53–59;
Google Scholar
G. P. Ford, P. S. Herman, ‘Relative stability of nitrenium ions derived from polycyclic aromatic amines. Relationship to mutagenicity’, Chem.-Biol. Interact. 1992, 81, 1–18;
Google Scholar
G. P. Ford, G. R. Griffin, ‘Relative stability of nitrenium ions derived from heterocyclic amine food carcinogens. Relationship to mutagenicity’, Chem.-Biol. Interact. 1992, 81, 19–33;
Google Scholar
R. S. Kerdar, D. Dehner, D. Wild, ‘Reactivity and genotoxicity of arylnitrenium ions in bacterial and mammalian cells’, Toxicol. Lett. 1993, 67, 73–85.
Google Scholar
157 M. D. Tingle, R. Mahmud, J. L. Maggs, M. Pirmohamed, B. K. Park, ‘Comparison of the metabolism and toxicity of dapsone in rat, mouse and man’, J. Pharmacol. Exp. Ther. 1997, 283, 817–823.
Google Scholar
158 R. P. Reilly, F. H. Bellevue III, P. M. Woster, C. K. Svensson, ‘Comparison of the in vitro cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and dapsone’, Biochem. Pharmacol. 1998, 55, 803–810.
Google Scholar
159 A. E. Cribb, M. Miller, J. S. Leeder, J. Hill, S. P. Spielberg, ‘Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione’, Drug Metab. Dispos. 1991, 19, 900–906.
Google Scholar
160 A. E. Cribb, S. P. Spielberg, ‘Sulfamethoxazole is metabolized to the hydroxylamine in humans’, Clin. Pharmacol. Ther. 1992, 51, 522–526.
Google Scholar
161 R. J. Turesky, A. Constable, J. Richoz, N. Varga, J. Markovic, M. V. Martin, F. P. Guengerich, ‘Activation of heterocyclic aromatic amines by rat and human microsomes and by purified rat and human cytochrome P450 1A2’, Chem. Res. Toxicol. 1998, 11, 925–936.
Google Scholar
162 L. Koymans, G. M. Donné-Op den Kelder, J. M. te Koppele, N. P. E. Vermeulen, ‘Generalized cytochrome P450-mediated oxidation and oxygenation reactions in aromatic substrates with activated NH, OH, CH, or SH substituents’, Xenobiotica 1993, 23, 633–648.
Google Scholar
163 A. Dipple, C. J. Michejda, E. K. Weisburger, ‘Metabolism of chemical carcinogens’, Pharmacol. Ther. 1985, 27, 265–296.
Google Scholar
164 S. D. Nelson, ‘Arylamines and arylamides: Oxidation mechanisms’, in ‘Bioactivation of Foreign Compounds’, Ed. M. W. Anders, Academic Press, Orlando, 1985, p. 349–374.
Google Scholar
165 B. Lindeke, ‘The non- and postenzymatic chemistry of N-oxygenated molecules’, Drug Metab. Rev. 1982, 13, 71–121.
Google Scholar
166 L. Koymans, J. H. Van Lenthe, G. M. Donné-Op den Kelder, N. P. E. Vermeulen, ‘Mechanisms of oxidation of phenacetin to reactive metabolites by cytochrome P450: A theoretical study involving radical intermediates’, Mol. Pharmacol. 1990, 37, 452–460.
Google Scholar
167 A. W. Nichols, I. D. Wilson, M. Godejohann, I. K. Nicholson, J. P. Stockcor, ‘Identification of phenacetin metabolites in human urine after administration of phenacetin-C²H₃: Measurement of futile metabolic deacetylation vis HPLC/MS-SPE-NMR and HPLC-ToF MS’, Xenobiotica 2006, 36, 615–629.
Google Scholar
168 P. P. Fu, ‘Metabolism of nitro-polycyclic aromatic hydrocarbons’, Drug Metab. Rev. 1990, 22, 209–268.
Google Scholar
169 S. C. Mitchell, R. H. Waring, ‘The early history of xenobiotic sulfoxidation’, Drug Metab. Rev. 1985, 16, 255–284.
Google Scholar
170 S. Oae, A. Mikami, T. Matsuura, K. Ogawa-Asada, Y. Watanabe, K. Fujimori, T. Iyanagi, ‘Comparison of sulfide oxygenation mechanism for liver microsomal FAD-containing monooxygenase with that for cytochrome P-450’, Biochem. Biophys. Res. Commun. 1985, 131, 567–573.
Google Scholar
171 K. A. Usmani, E. D. Karoly, E. Hodgson, R. L. Rose, ‘In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily’, Drug Metab. Dispos. 2004, 32, 333–339.
Google Scholar
172 G. Caron, P. Gaillard, P. A. Carrupt, B. Testa, ‘Lipophilicity behavior of model and medicinal compounds containing a sulfide, sulfoxide, or sulfone moiety’, Helv. Chim. Acta 1997, 80, 449–462.
Google Scholar
173 D. D. S. Tang-Liu, R. M. Matsumoto, J. I. Usansky, ‘Clinical pharmacokinetics and drug metabolism of tazarotene’, Clin. Pharmacokinet. 1999, 37, 273–287.
Google Scholar
174 M. Attar, D. Dong, K. H. J. Ling, D. D. S. Tang-Liu, ‘Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotene acid in humans’, Drug Metab. Dispos. 2003, 31, 476–481.
Google Scholar
175 A. E. Rettie, M. P. Lawton, A. Jafar, M. Sadeque, G. P. Meier, R. M. Philpot, ‘Prochiral sulfoxidation as a probe for multiple forms of the microsomal flavin-containing monooxygenase: Studies with rabbit FMO1, FMO2, FMO3 and FMO5 expressed in Escherichia coli’, Arch. Biochem. Biophys. 1994, 311, 369–377.
Google Scholar
176 J. R. Cashman, ‘Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P450 monooxygenases’, Drug Metab. Rev. 1998, 30, 675–707.
Google Scholar
177 H. B. Hucker, S. C. Stauffer, S. D. White, R. E. Rhodes, B. H. Arison, E. R. Umbenhauer, R. J. Bower, F. G. McMahon, ‘Physiologic disposition and metabolic fate of a new anti-inflammatory agent, sulindac in the rat, dog, rhesus monkey, and man’, Drug Metab. Dispos. 1973, 1, 721– 736.
Google Scholar
178 M. A. Hamman, B. D. Haehner-Daniels, S. A. Wrighton, A. E. Rettie, S. D. Hall, ‘Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases’, Biochem. Pharmacol. 2000, 60, 7–17.
Google Scholar
179 D. M. Ziegler, ‘Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases’, Annu. Rev. Pharmacol. Toxicol. 1993, 33, 179–199.
Google Scholar
180 K. L. Taylor, D. M. Ziegler, ‘Studies on substrate specificity of the hog liver flavin-containing monooxygenase. Anionic organic sulfur compounds’, Biochem. Pharmacol. 1987, 36, 141–146.
Google Scholar
181 C. J. Decker, M. S. Rashed, T. A. Baillie, D. Maltby, M. A. Correia, ‘Oxidative metabolism of spironolactone: evidence for the involvement of electrophilic thiosteroid species in drug-mediated destruction of rat hepatic cytochrome P450’, Biochemistry 1989, 28, 5128–5136.
Google Scholar
182 C. J. Decker, J. R. Cashman, K. Sugiyama, D. Maltby, M. A. Correia, ‘Formation of glutathionyl-spironolactone disulfide by rat liver cytochromes P450 or hog liver flavin-containing monooxygenases: a functional probe of two-electron oxidations of the thiosteroid’, Chem. Res. Toxicol. 1991, 4, 669–677.
Google Scholar
183 C. Teyssier, L. Guenot, M. Suschetet, M. H. Siess, ‘Metabolism of diallyl disulfide by human liver microsomal cytochromes P450 and flavin-containing monooxygenases’, Drug Metab. Dispos. 1999, 27, 835–841.
Google Scholar
184 E. Germain, J. Chevalier, M. H. Siess, C. Teyssier, ‘ Hepatic metabolism of diallyl disulfide in rat and man’, Xenobiotica 2003, 33, 1185–1199.
Google Scholar
185 C. J. Decker, D. R. Doerge, ‘Covalent binding of ¹⁴C- and ³⁵S-labeled thiocarbamides in rat hepatic microsomes’, Biochem. Pharmacol. 1992, 43, 881–888.
Google Scholar
186 M. C. Dyroff, R. A. Neal, ‘Studies of the mechanism of metabolism of thioacetamide S-oxide by rat liver microsomes’, Mol. Pharmacol. 1983, 23, 219–227.
Google Scholar
187 T. A. Vannelli, A. Dykman, P. R. Ortiz de Montellano, ‘The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase’, J. Biol. Chem. 2002, 277, 12824–12829.
Google Scholar
188 J. Halpert, D. Hammond, R. A. Neal, ‘Inactivation of purified rat liver cytochrome P450 during the metabolism of parathion (diethyl p-nitrophenyl phosphorothionate)’, J. Biol. Chem. 1980, 255, 1080–1089.
Google Scholar
189 N. P. E. Vermeulen, J. G. M. Bessems, R. van de Straat, ‘Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention’, Drug Metab. Rev. 1992, 24, 367–407.
Google Scholar
190 C. J. Patten, P. E. Thomas, R. L. Guy, M. Lee, F. J. Gonzalez, F. P. Guengerich, C. S. Yang, ‘Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics’, Chem. Res. Toxicol. 1993, 6, 511–518.
Google Scholar
191 S. S. T Lee, J. T. M: Buters, T. Pineau, P. Fernandez Alguero, F. J. Gonzalez, ‘Role of CYP2E1 in the hepatotoxicity of acetaminophen’, J. Biol. Chem. 1996, 271, 12063–12067.
Google Scholar
192 J. G. M. Bessems, M. J. de Groot, E. J. Baede, J. M. te Koppele, N. P. E. Vermeulen, ‘ Hydrogen atom abstraction of 3,5-disubstituted analogues of paracetamol by horseradish peroxidase and cytochrome P450’, Xenobiotica 1998, 28, 855–875.
Google Scholar
193 D. C. Thompson, J. A. Thompson, M. Sugumaran, P. Moldéus, ‘Biological and toxicological consequences of quinone methide formation’, Chem.-Biol. Interact. 1992, 86, 129–162.
Google Scholar
194 J. A. Thompson, A. M. Malkinson, M. D. Wand, S. L. Mastovich, E. W. Mead, K. M. Schullek, W. G. Laudenschlager, ‘Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice’, Drug Metab. Dispos. 1987, 15, 833–840.
Google Scholar
195 A. Kamel, J. Davis, M. J. Potchoiba, C. Prakash, ‘Metabolism, pharmacokinetic and excretion of a potent tachykinin NK1 receptor antagonist (CP-122,721) in rat: Characterization of a novel oxidative pathway’, Xenobiotica 2006, 36, 235–258.
Google Scholar
196 M. R. Anari, S. Khan, S. D. Jatoe, P. J. O'Brien, ‘Cytochrome P450-dependent xenobiotic activation by physiological hydroperoxides in intact hepatocytes’, Eur. J. Drug Metab. Pharmacokinet. 1997, 22, 305–310.
Google Scholar
197 M. Y. Wang, J. G. Liehr, ‘Identification of fatty acid hydroperoxide cofactors in the cytochrome P450-mediated oxidation of estrogens to quinone metabolites’, J. Biol. Chem. 1994, 269, 284– 291.
Google Scholar
198 M. R. Anari, P. D. Josephy, T. Henry, P. J. O'Brien, ‘ Hydrogen peroxide supports human and rat cytochrome P450 1A2-catalyzed 2-amino-3-methylimidazo[4,5-f]quinoline bioactivation to mutagenic metabolites: Significance of cytochrome P450 peroxidase’, Chem. Res. Toxicol. 1997, 10, 582–588.
Google Scholar
199 R. W. Chadwick, S. E. George, L. D. Claxton, ‘Role of the gastrointestinal mucosa and microflora in the bioactivation of dietary and environmental mutagens or carcinogens’, Drug Metab. Rev. 1992, 24, 425–492.
Google Scholar
200 D. R. Koop, ‘Oxidative and reductive metabolism by cytochrome P450 2E1’, FASEB J. 1992, 6, 724–730.
Google Scholar
201 A. R. Goeptar, H. Scheerens, N. P. E. Vermeulen, ‘Oxygen and xenobiotic reductase activities by cytochrome P450’, Crit. Rev. Toxicol. 1995, 25, 25–65.
Google Scholar
202 D. Perrissoud, B. Testa, ‘Inhibiting or potentiating effects of flavonoids on carbon tetrachloride-induced toxicity in isolated rat hepatocytes’, Arzneim.-Forsch. (Drug Res.) 1986, 36, 1249– 1253.
Google Scholar
203 W. R. Jondorf, ‘Drug metabolism and drug toxicity: Some evolutionary considerations’, in ‘Concepts in Drug Metabolism, Part B’, Eds. P. Jenner, B. Testa, Dekker, New York, 1981, p. 307–376.
Google Scholar
204 W. R. Kelce, C. R. Stone, S. C. Laws, L. E. Gray, J. A. Kemppainen, E. M. Wilson, ‘Persistent DDT metabolite p,p′-DDE is a potent androgen receptor antagonist’, Nature 1995, 375, 581–585.
Google Scholar
205 M. Manno, S. Cazzaro, M. Rezzadore, ‘The mechanism of the suicidal reductive inactivation of microsomal cytochrome P-450 by halothane’, Arch. Toxicol. 1991, 65, 191–198.
Google Scholar
206 D. K. Spracklin, K. E. Thummel, E. D. Kharasch, ‘ Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4’, Drug Metab. Dispos. 1991, 24, 976–983.
Google Scholar
207 A. K. Fröhlich, U. Girreser, B. Clement, ‘Metabolism of benzamidoxime (N-hydroxyamidine) in human hepatocytes and role of UDP-glucuronosyltransferases’, Xenobiotica 2005, 35, 17–25.
Google Scholar
208 S. Heberling, U. Girreser, S. Wolf, B. Clement, ‘Oxygen-insensitive enzymatic reduction of oximes to imines’, Biochem. Pharmacol. 2006, 71, 354–365.
Google Scholar
209 B. Clement, ‘Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as prodrugs of amidines’, Drug Metab. Rev. 2002, 34, 565–579.
Google Scholar
210 S. Zbaida, C. F. Brewer, W. G. Levine, ‘Substrates for microsomal azoreductase. Hammett substituent effects, NMR studies and response to inhibitors’, Drug Metab. Dispos. 1992, 20, 902–908.
Google Scholar
211 W. G. Levine, A. Stoddart, S. Zbaida, ‘Multiple mechanisms in hepatic microsomal azoreduction’, Xenobiotica 1992, 22, 1111–1120.
Google Scholar
212 S. Zbaida, ‘The mechanism of microsomal azoreduction: predictions based on electronic aspects of structure–activity relationships’, Drug Metab. Rev. 1995, 27, 497–516.
Google Scholar
213 E. M. Cretton, J. P. Sommadossi, ‘Reduction of 3′-azido-2′,3′-dideoxynucleosides to their 3′-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes’, Drug Metab. Dispos. 1993, 21, 946–950.
Google Scholar
214 X. R. Pan-Zhou, E. Cretton-Scott, X. J. Zhou, M. X. Yang, J. M. Lasker, J. P. Sommadossi, ‘Role of human liver P450s and cytochrome b₅ in the reductive metabolism of 3′-azido-3′-deoxythymidine (AZT) to 3′-amino-3′-deoxythymidine’, Biochem. Pharmacol. 1998, 55, 757–766.
Google Scholar
215 J. E. Biaglow, M. E. Varnes, L. Roizen-Towle, E. P. Clark, E. R. Epp, M. B. Astor, E. J. Hall, ‘Biochemistry of reduction of nitro heterocycles’, Biochem. Pharmacol. 1986, 35, 77–90.
Google Scholar
216 V. Purohit, A. K. Basu, ‘Mutagenicity of nitroaromatic compounds’, Chem. Res. Toxicol. 2000, 13, 673–692.
Google Scholar
217 J. Butler, B. M. Hoey, ‘The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase’, Biochim. Biophys. Acta 1993, 1161, 73– 78.
Google Scholar
218 J. J. R. Hermans, H. H. W. Thijssen, ‘Comparison of the rat liver microsomal metabolism of the enantiomers of warfarin and 4′-nitrowarfarin (acenocoumarol)’, Xenobiotica 1991, 21, 295–307.
Google Scholar
219 K. Ask, N. Décologne, C. Ginies, M. Låg, J. L. Boucher, J. A. Holme, H. Pelczar, P. Camus, ‘Metabolism of nilutamide in rat lung’, Biochem. Pharmacol. 2006, 71, 377–395.
Google Scholar
220 W. N. Wu, L. A. McKown, S. Liao, ‘Metabolism of the analgesic drug ULTRAM^® (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites’, Xenobiotica 2002, 32, 411–425.
Google Scholar
221 W. N. Wu, L. A. McKown, E. E. Codd, R. B. Raffa, ‘Metabolism of two analgesic agents, tramadol N-oxide and tramadol, in specific pathogen-free and axenic mice’, Xenobiotica 2006, 36, 551–565.
Google Scholar
222 S. M. Raleigh, E. Wanogho, M. D. Burke, L. H. Patterson, ‘Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug’, Xenobiotica 1999, 29, 1115–1122.
Google Scholar
223 P. M. Loadman, D. J. Swaine, M. C. Bibby, K. J. Welham, L. H. Patterson, ‘A preclinical pharmacokinetic study of the bioreductive drug AQ4N’, Drug Metab. Dispos. 2001, 29, 422–426.
Google Scholar
224 D. Lang, A. S. Kalgutkar, ‘Non-P450 mediated oxidative metabolism of xenobiotics’, In ‘Drug Metabolizing Enzymes. Cytochrome P450 and Other Enzymes in Drug Discovery and Development’, J. Lee, R. S. Obach, M. B. Fisher, Eds. Dekker, New York, 2003, p. 483–540.
Google Scholar
225 M. B. H. Youdim, J. P. M. Finberg, ‘New directions in monoamine oxidase A and B selective inhibitors and substrates’, Biochem. Pharmacol. 1991, 41, 155–162.
Google Scholar
226 G. Maret, B. Testa, P. Jenner, N. El Tayar, P. A. Carrupt, ‘The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism’, Drug Metab. Rev. 1990, 22, 291–332.
Google Scholar
227 T. J. Mantle, K. F. Tipton (Eds.), ‘Amine oxidases: structure, function and expression’, Biochem. Trans. 1991, 19, 199–233.
Google Scholar
228 M. Strolin Benedetti, P. Dostert, ‘Contribution of amine oxidases to the metabolism of xenobiotics’, Drug Metab. Rev. 1994, 26, 507–535.
Google Scholar
229 M. Strolin Benedetti, K. F. Tipton, ‘Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics’, J. Neural Transm. 1998, 52(Suppl.), 149–171.
Google Scholar
230 M. Strolin Benedetti, ‘Biotransformation of xenobiotics by amine oxidases’, Fundam. Clin. Pharmacol. 2001, 15, 75–84.
Google Scholar
231 P. J. O'Brien, A. G. Siraki, N. Shangari, ‘Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health’, Crit. Rev. Toxicol. 2005, 35, 609–662.
Google Scholar
232 B. Gong, P. J. Boor, ‘The role of amine oxidases in xenobiotic metabolism’, Expert Opin. Drug Metab. Toxicol. 2006, 2, 559–571.
Google Scholar
233 J. P. Klinman, D. Mu, ‘Quinoenzymes in biology’, Annu. Rev. Biochem. 1994, 63, 299–344.
Google Scholar
234 R. Medda, A. Padiglia, J. Z. Pedersen, G. Rotilio, A. Finazzi Agrò, G. Floris, ‘The reaction mechanism of copper amine oxidase: detection of intermediates by the use of substrates and inhibitors’, Biochemistry 1995, 34, 16375–16381.
Google Scholar
235 A. High, T. Prior, R. A. Bell, P. K. Rangachari, ‘Probing the ‘active site’ of diamine oxidase : structure–activity relations for histamine potentiation by O-alkylhydroxylamines on colonic epithelium', J. Pharmacol. Exp. Ther. 1999, 288, 490–501.
Google Scholar
236 E. Y. Wang, H. Gao, L. Salter-Cid, J. Zhang, L. Huang, E. M. Podar, A. Miller, J. Zhao, A. O'Rourke, M. D. Linnik, ‘Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity’, J. Med. Chem. 2006, 49, 2166–2173.
Google Scholar
237 R. B. Silverman, ‘Radical ideas about monoamine oxidase’, Acc. Chem. Res. 1995, 28, 335–342.
Google Scholar
238 W. Weyler, Y. P. P. Hsu, X. O. Breakefield, ‘Biochemistry and genetics of monoamine oxidase’, Pharmacol. Ther. 1990, 47, 391–417.
Google Scholar
239 A. M. Yu, C. P. Granvil, R. L. Haining, K. W. Krausz, J. Corchero, A. Küpfer, J. R. Idle, F. J. Gonzalez, ‘The relative contribution of monoamine oxidase and cytochrome P450 isozymes to the metabolic deamination of the trace amine tryptamine’, J. Pharmacol. Exp. Ther. 2003, 304, 539–546.
Google Scholar
240 N. Castagnoli Jr., J. M. Rimoldi, J. Bloomquist, K. P. Castagnoli, ‘Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes’, Chem. Res. Toxicol. 1997, 10, 924–940.
Google Scholar
241 A. S. Kalgutkar, D. K. Dalvie, N. Castagnoli Jr., T. J. Taylor, ‘Interactions of nitrogen-containing xenobiotics with MAO-A and MAO-B: SAR studies on MAO substrates and inhibitors’, Chem. Res. Toxicol. 2001, 14, 1139–1162.
Google Scholar
242 N. Castagnoli Jr., K. P. Castagnoli, G. Magnin, S. Kuttab, J. Shang, ‘Studies on the oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridines’, Drug Metab. Rev. 2002, 34, 533–547.
Google Scholar
243 B. Rochat, M. Kossel, G. Boss, B. Testa, M. Gillet, P. Baumann, ‘Stereoselective biotransformation of the SSRI citalopram and its demethylated metabolites by monoamine oxidases in human liver’, Biochem. Pharmacol. 1998, 56, 15–23.
Google Scholar
244 M. Kossel, C. Gnerre, P. Voirol, M. Amey, B. Rochat, C. Bouras, B. Testa, P. Baumann, ‘In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations’, Mol. Psychiat. 2002, 7, 181–188.
Google Scholar
245 M. Salva, J. M. Jansat, A. Martinez-Tobed, J. M. Palacios, ‘Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan’, Drug Metab. Dispos. 2003, 31, 404–411.
Google Scholar
246 P. H. Yu, B. A. Davis, A. A. Boulton, ‘Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors’, J. Med. Chem. 1992, 35, 3705–3713.
Google Scholar
247 P. H. Yu, B. A. Davis, ‘Stereospecific deamination of benzylamine catalyzed by different amine oxidases’, Int. J. Biochem. 1988, 20, 1197–1201.
Google Scholar
248 G. Alton, T. H. Taher, R. J. Beever, M. M. Palcic, ‘Stereochemistry of benzylamine oxidation by copper amine oxidases’, Arch. Biochem. Biophys. 1995, 316, 353–361.
Google Scholar
249 F. Yraola, S. Garcia-Vicente, J. Fernandez-Reccio, F. Albericio, A. Zorzano, L. Marti, M. Royo, ‘New efficient substrates for SSAO/VAP-1 enzyme: analysis by SARs and computational docking’, J. Med. Chem. 2006, 49, 6197–6208.
Google Scholar
250 A. P. Beresford, P. V. Macrae, D. A. Stopher, ‘Metabolism of amlodipine in the rat and dog: a species difference’, Xenobiotica 1988, 18, 169–182.
Google Scholar
251 R. Hille, ‘Molybdenum-containing hydroxylases’, Arch. Biochem. Biophys. 2005, 433, 107–116.
Google Scholar
252 E. Garattini, R. Mendel, M. J. Romao, R. Wright, M. Terao, ‘Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology’, Biochem. J. 2003, 372, 15–32.
Google Scholar
253 K. Okamoto, K. Matsumoto, R. Hille, B. T. Eger, E. F. Pai, T. Nishino, ‘The crystal structure of xanthine oxidoreductase during catalysis: Implications for reaction mechanism and enzyme inhibition’, Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 7931–7936.
Google Scholar
254 M. Terao, M. Kurosaki, M. M. Barzago, E. Varasano, A. Boldetti, A. Bastone, M. Fratelli, E. Garattini, ‘Avian and canine aldehyde oxidases: Novel insights into the biology and evolution of molybdo-flavoenzymes’, J. Biol. Chem. 2006, 281, 19748–19761.
Google Scholar
255 R. Harrison, ‘Physiological roles of xanthine oxidoreductase’, Drug Metab. Rev. 2004, 36, 363–375.
Google Scholar
256 R. Hille, ‘The reaction mechanism of oxomolybdenum enzymes’, Biochim. Biophys. Acta 1994, 1184, 143–169.
Google Scholar
257 S. Kitamura, K. Sugihara, S. Ohta, ‘Drug-metabolizing ability of molybdenum hydroxylases’, Drug Metab. Pharmacokinet. 2006, 21, 83–96.
Google Scholar
258 F. Lacy, D. A. Gough, G. W. Schmid-Schönbein, ‘Role of xanthine oxidase in hydrogen peroxide production’, Free Radical Biol. Med. 1998, 25, 720–727.
Google Scholar
259 C. Galbusera, P. Orth, D. Fedida, T. Spector, ‘Superoxide radical production by allopurinol and xanthine oxidase’, Biochem. Pharmacol. 2006, 71, 1747–1752.
Google Scholar
260 C. Beedham, ‘Molybdenum hydroxylases as drug-metabolizing enzymes’, Drug Metab. Rev. 1985, 16, 119–156.
Google Scholar
261 C. Beedham, ‘The role of non-P450 enzymes in drug oxidation’, Pharm. World Sci. 1997, 19, 255–263.
Google Scholar
262 G. Rastelli, L. Costantino, A. Albasini, ‘A model of the interaction of substrates and inhibitors with xanthine oxidase’, J. Am. Chem. Soc. 1997, 119, 3007–3016.
Google Scholar
263 D. O'Connor, P. Jones, M. S. Chambers, R. Maxey, H. J. Szekeres, N. Szeto, P. Scott-Stevens, A. M. Macleod, M. Braun, B. Cato, ‘Aldehyde oxidase and its contribution to the metabolism of a structurally novel, functionally selective GABA_A α5-subtype inverse agonist’, Xenobiotica 2006, 36, 315–330.
Google Scholar
264 K. Sugihara, Y. Tayama, K. Shimomiya, D. Yoshimoto, S. Ohta, S. Kitamura, ‘Estimation of aldehyde oxidase activity in vivo from conversion ratio of N¹-methylnicotinamide to pyridones, and interspecies variation of the enzyme activity in rats’, Drug Metab. Dispos. 2006, 34, 208–212.
Google Scholar
265 Y. Moriwaki, T. Yamamoto, Y. Nasako, S. Takahashi, M. Suda, K. Hiroishi, T. Hada, K Higashino, ‘In vitro oxidation of pyrazinamide and allopurinol by rat liver aldehyde oxidase’, Biochem. Pharmacol. 1993, 46, 975–981.
Google Scholar
266 G. I. Panoutsopoulos, D. Kouretas, C. Beedham, ‘Contribution of aldehyde oxidase, xanthine oxidase, and aldehyde dehydrogenase on the oxidation of aromatic aldehydes’, Chem. Res. Toxicol. 2004, 17, 1368–1376.
Google Scholar
267 D. C. Lewis, T. Shibamoto, ‘Relative metabolism of quinones to semiquinone radicals in xanthine oxidase system’, J. Appl. Toxicol. 1989, 9, 291–295.
Google Scholar
268 D. Roy, B. Kalyanaraman, J. G. Liehr, ‘Xanthine oxidase-catalyzed reduction of estrogen quinones to semiquinones and hydroquinones’, Biochem. Pharmacol. 1991, 42, 1627–1631.
Google Scholar
269 O. Ueda, S. Kitamura, K. Ohashi, K. Sugihara, S. Ohta, ‘Xanthine oxidase-catalyzed metabolism of 2-nitrofluorene, a carcinogenic air pollutant, in rat skin’, Drug Metab. Dispos. 2003, 31, 367– 372.
Google Scholar
270 R. I. Sanchez, S. Mesia-Vela, F. C. Kauffman, ‘Challenges of cancer drug design: a drug metabolism perspective’, Curr. Cancer Drug Targets 2001, 1, 1–32.
Google Scholar
271 P. Reigan, P. N. Edwards, A. Gbaj, C. Cole, S. T. Barry, K. M. Page, S. E. Ashton, R. W. A. Luke, K. T. Douglas, I. J. Stratford, M. Jaffar, R. A. Bryce, S. Freeman, ‘Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bireductive nitroimidazolyl prodrugs’, J. Med. Chem. 2005, 48, 392–402.
Google Scholar
272 C. Beedham, J. Miceli, R. S. Obach, ‘Ziprasidone metabolism, aldehyde oxidase, and clinical implications’, J. Clin. Psychopharmacol. 2003, 23, 229–232.
Google Scholar
273 P. J. O'Brien, ‘Peroxidases’, Chem.-Biol. Interact. 2000, 129, 113–139.
Google Scholar
274 S. Tafazoli, P. J. O'Brien, ‘Peroxidases: a role in the metabolism and side effects of drugs’, Drug Discov. Today 2005, 10, 617–625.
Google Scholar
275 H. B. Dunford, ‘One-electron oxidations by peroxidases’, Xenobiotica 1995, 25, 725–733.
Google Scholar
276 J. P. Uetrecht, ‘The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions’, Drug Metab. Rev. 1992, 24, 299–366.
Google Scholar
277 J. R. Vane, Y. S. Bakhle, R. M. Botting, ‘Cyclooxygenases 1 and 2’, Annu. Rev. Pharmacol. Toxicol. 1998, 38, 97–120.
Google Scholar
278 J. R. Kiefer, J. L. Pawlitz, K. T. Moreland, R. A. Stegeman, W. F. Hood, J. K. Glerse, A. M. Stevens, D. C. Goodwin, S. W. Rowlinson, L. J. Marnett, W. C. Stallings, R. G. Kurumball, ‘Structural insights into the stereochemistry of the cyclooxygenase reaction’, Nature 2000, 405, 97–101.
Google Scholar
279 T. E. Eling, J. F. Curtis, ‘Xenobiotic metabolism by prostaglandin H synthase’, Pharmacol. Ther. 1992, 53, 261–273.
Google Scholar
280 T. E. Eling, D. C. Thompson, G. L. Foureman, J. F. Curtis, M. F. Hughes, ‘Prostaglandin H synthase and xenobiotic oxidation’, Annu. Rev. Pharmacol. Toxicol. 1990, 30, 1–45.
Google Scholar
281 R. Goldman, G. H. Claycamp, M. A. Sweetland, A. V. Sedlov, V. A. Tyurin, E. R. Kisin, Y. Y. Tyurnina, V. B. Ritov, S. L. Wenger, S. G. Grant, V. E. Kagan, ‘Myeloperoxidase-catalyzed redox-cycling of phenol promotes lipid peroxidation and thiol oxidation in HL-60 cells’, Free Radical Biol. Med. 1999, 27, 1050–1063.
Google Scholar
282 D. A. Eastmond, M. T. Smith, L. O. Ruzo, D. Ross, ‘Metabolic activation of phenol by human myeloperoxidase and horseradish peroxidase’, Mol. Pharmacol. 1986, 30, 674–679.
Google Scholar
283 J. Dai, A. L. Sloat, M. W. Wright, R. A. Manderville, ‘Role of phenoxyl radicals in DNA adduction by chlorophenol xenobiotics following peroxidase activation’, Chem. Res. Toxicol. 2005, 18, 771–779.
Google Scholar
284 L. G. Ganousis, D. Goon, T. Zyglewska, K. K. Wu, D. Ross, ‘Cell-specific metabolism in mouse bone marrow stroma: studies of activation and detoxification of benzene metabolites’, Mol. Pharmacol. 1992, 42, 1118–1125
Google Scholar
285 R. Snyder, C. C. Hedli, ‘An overview of benzene metabolism’, Environ. Health Perspect. 1996, 104, 1165–1171.
Google Scholar
286 R. V. Bhat, V. V. Subrahmanyam, A. Sadler, D. Ross, ‘Bioactivation of catechol in rat and human bone marrow cells’, Toxicol. Appl. Pharmacol. 1988, 94, 297–304
Google Scholar
287 R. J. Boatman, J. C. English, L. G. Perry, L. A. Fiorica, ‘Covalent protein adducts of hydroquinone in tissues from rats: identification of quantification of sulfhydryl-bound forms’, Chem. Res. Toxicol. 2000, 13, 853–860.
Google Scholar
288 A. S. Kalgutkar, D. K. Dalvie, J. P. O'Donnell, T. J. Taylor, D. C. Sahakian, ‘On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics’, Curr. Drug Metab. 2002, 3, 379–424.
Google Scholar
289 J. L. Maggs, D. Williams, M. Pirmohamed, B. K. Park, ‘The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man’, J. Pharmacol. Exp. Ther. 1995, 275, 1463–1475.
Google Scholar
290 K. S. Smith, P. L. Smith, T. N. Heady, J. M. Trugman, W. D. Harman, T. L. Macdonald, ‘In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity’, Chem. Res. Toxicol. 2003, 16, 123–128.
Google Scholar
291 L. J. Marnett, P. Wlodawer, B. Samuelsson, ‘Co-oxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland’, J. Biol. Chem. 1975, 250, 8510–8517.
Google Scholar
292 P. J. Harvison, R. W. Egan, P. H. Gale, G. D. Christian, B. S. Hill, S. D. Nelson, ‘Acetaminophen and analogs as cosubstrates and inhibitors of prostaglandin H synthase’, Chem.-Biol. Interact. 1988, 64, 251–266.
Google Scholar
293 J. F. Curtis, K. Tomer, S. McGown, T. E. Eling, ‘Prostaglandin H synthase-catalyzed ring oxygenation of 2-naphthylamine: evidence for two distinct oxidation pathways’, Chem. Res. Toxicol. 1995, 8, 875–883.
Google Scholar
294 L. M. Winn, P. G. Wells, ‘Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis’, Free Radical Biol. Med. 1997, 22, 607–621.
Google Scholar
295 T. Patman, M. J. Wiley, P. G. Wells, ‘Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity’, Nature Med. 1999, 5, 582–585.
Google Scholar
296 M. J. Cox Rosemond, J. S. Walsh, ‘ Human carbonyl reduction pathways and a strategy for their study in vitro’, Drug Metab. Rev. 2004, 36, 335–361.
Google Scholar
297 U. C. T. Oppermann, E. Maser, ‘Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions’, Toxicology 2000, 144, 71–81.
Google Scholar
298 E. Maser, ‘Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases’, Biochem. Pharmacol. 1995, 49, 421–440.
Google Scholar
299 G. Duester, J. Farrés, M. R. Felder, R. S. Holmes, J. O. Höög, X. Parés, B. V. Plapp, S. J. Yin, H. Jörnvall, ‘Recommended nomenclature for the vertebrate alcohol dehydrogenase gene family’, Biochem. Pharmacol. 1999, 58, 389–395.
Google Scholar
300 G. Duester, ‘Families of retinoid dehydrogenases regulating vitamin A function’, Eur. J. Biochem. 2000, 267, 4315–4324.
Google Scholar
301 H. Jörnvall, E. Nordling, B. Persson, ‘Multiplicity of eukaryotic ADH and other forms’, Chem.-Biol. Interact. 2003, 143–144, 255–261.
Google Scholar
302 B. L. Vallee, D. S. Auld, ‘Zinc coordination, function and structure of zinc enzymes and other proteins’, Biochemistry 1990, 29, 5647–5659.
Google Scholar
303 F. L. Gervasio, V. Schettino, S. Mangani, M. Krack, P. Carloni, M. Parrinello, ‘Influence of outer-shell metal ligands on the structural and electronic properties of horse liver alcohol dehydrogenase zinc active site’, J. Phys. Chem. 2003, 107, 6886–6892.
Google Scholar
304 M. Frezza, C. di Padova, G. Pozzato, M. Terpin, E. Baraona, C. S. Lieber, ‘ High blood alcohol levels in women’, N. Engl. J. Med. 1990, 322, 95–99.
Google Scholar
305 M. Radel, D. Goldman, ‘Pharmacogenetics of alcohol response and alcoholism: the interplay of genes and environmental factors in thresholds for alcoholism’, Drug Metab. Dispos. 2001, 29, 489–494.
Google Scholar
306 V. Vasiliou, A. Pappa, T. Estey, ‘Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism’, Drug Metab. Rev. 2004, 36, 279–299.
Google Scholar
307 V. Vasiliou, A. Bairoch, K. F. Tipton, D. W. Nebert, ‘Eukaryotic aldehyde dehydrogenase (ALDH) genes: human polymorphism, and recommended nomenclature based on divergent evolution and chromosomal mapping’, Pharmacogenetics 1999, 9, 421–434; www.aldh.org.
Google Scholar
308 V. Vasiliou, A. Pappa, ‘Polymorphisms of human aldehyde dehydrogenases’, Pharmacology 2000, 61, 192–198.
Google Scholar
309 J. S. Rodriguez-Zavala, H. Weiner, ‘Structural aspects of aldehyde dehydrogenase that influence dimer-tetramer formation’, Biochemistry 2002, 41, 8229–8237.
Google Scholar
310 J. M. Jez, T. G. Flynn, T. M. Penning, ‘A new nomenclature for the aldo-keto reductase superfamily’, Biochem. Pharmacol. 1997, 54, 639–647;
Google Scholar
D. Hyndman, D. R. Bauman, V. V. Heredia, T. M. Penning, ‘The aldo-keto reductase superfamily homepage’, Chem.-Biol. Interact. 2003, 143–144, 621–631; www.med.upenn.edu/akr/.
Google Scholar
311 T. M. Penning, Y. Jin, S. Steckelbroeck, T. Lanisnik Rizner, M. Lewis, ‘Structure-function of human 3α-hydroxy steroid dehydrogenases: genes and proteins’, Mol. Cell. Endocrinol. 2004, 215, 63–72.
Google Scholar
312 H. K. Lin, C. F. Hung, M. Moore, T. M. Penning, ‘Genomic structure of rat 3α-hydroxysteroid/dihydrodiol dehydrogenase (3α-HSD/DD, AKR1C9)’, J. Steroid Biochem. Mol. Biol. 1999, 71, 29–39.
Google Scholar
313 T. Ozeki, Y. Takahashi, T. Kume, K. Nakayama, T. Yokoi, K. I. Nunoya, A. Hara, T. Kamataki, ‘Co-operative regulation of the transcription of human dihydrodiol dehydrogenase DD4/aldo-keto reductase AKR1C4 gene by hepatocyte nuclear factor (HNF)-4α/γ and HNF-1α’, Biochem. J. 2001, 355, 537–544.
Google Scholar
314 F. P. Guengerich, H. Cai, M. McMahon, J. D. Hayesm T. R. Sutter, J. D. Groopman, Z. Deng, T. M. Harris, ‘Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases’, Chem. Res. Toxicol. 2001, 14, 727–737.
Google Scholar
315 G. L. Forrest, B. Gonzalez, ‘Carbonyl reductases’, Chem.-Biol. Interact. 2000, 129, 21–40.
Google Scholar
316 A. Blum, A. Raum, H. J. Martin, E. Maser, ‘ Human 11β-hydroxysteroid dehydrogenase 1/carbonyl reductase: additional domains for membrane attachment’, Chem.-Biol. Interact. 2001, 130–132, 749–759.
Google Scholar
317 M. E. Baker, ‘Rat 3α-hydroxysteroid dehydrogenase: to oxidize or reduce, that is the question’, Endocrinology 2006, 147, 1589–1590.
Google Scholar
318 S. S. Lakhman, D. Ghosh, J. B. Blanco, ‘Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)’, Drug Metab. Dispos. 2005, 33, 254–257.
Google Scholar
319 D. Ross, ‘Quinone reductases multitasking in the metabolic world’, Drug Metab. Rev. 2004, 36, 639–654.
Google Scholar
320 C. E. Foster, M. A. Bianchet, P. Talalay, M. Faig, L. M. Amzel, ‘Structures of mammalian cytosolic quinone reductases’, Free Radical Biol. Med. 2000, 29, 241–245.
Google Scholar
321 S. Chen, K. Wu, R. Knox, ‘Structure–function studies of DT-diaphorase (NQO1) and NRH : quinone oxidoreductase (NQO2)’, Free Radical Biol. Med. 2000, 29, 276–284.
Google Scholar
322 D. J. Long II, A. K. Jaiswal, ‘NRH:quinone oxidoreductase 2 (NQO2)’, Chem.-Biol. Interact. 2000, 129, 99–112.
Google Scholar
323 F. Vella, G. Ferry, P. Delagrange, J. A. Boutin, ‘NRH : quinone reductase 2: an enzyme of surprises and mysteries’, Biochem. Pharmacol. 2005, 71, 1–12.
Google Scholar
324 L. P. Olson, J. Luo, Ö. Almarsson, T. C. Bruice, ‘Mechanism of aldehyde oxidation catalyzed by horse liver alcohol dehydrogenase’, Biochemistry 1996, 35, 9782–9791.
Google Scholar
325 S. Ramaswamy, H. Eklund, B. V. Plapp, ‘Structures of horse live alcohol dehydrogenase complexed with NAD⁺ and substituted benzyl alcohols’, Biochemistry 1994, 33, 5230–5237.
Google Scholar
326 P. K. Agarwal, S. P. Webb, S. Hammes-Schiffer, ‘Computational studies on the mechanism for proton and hydride transfer in liver alcohol dehydrogenase’, J. Am. Chem. Soc. 2000, 122, 4803– 4812.
Google Scholar
327 L. A. LeBrun, D. H. Park, S. Ramaswamy, B. V. Plapp, ‘Participation of histidine-51 in catalysis by horse liver alcohol dehydrogenase’, Biochemistry 2004, 43, 3014–3026.
Google Scholar
328 A. A. Klyosov, ‘Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes’, Biochemistry 1996, 35, 4457–4467.
Google Scholar
329 A. A. Klyosov, L. G. Rashkovetsky, M. K. Tahir, W. M. Keung, ‘Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism’, Biochemistry 1996, 35, 4445–4456.
Google Scholar
330 F. R. Fontaine, R. A. Dunlop, D. R. Petersen, P. C. Burcham, ‘Oxidative bioactivation of crotyl alcohol to the toxic endogenous aldehyde crotonaldehyde: association of protein carbonylation with toxicity in mouse hepatocytes’, Chem. Res. Toxicol. 2002, 15, 1051–1058.
Google Scholar
331 R. Lindahl, ‘Aldehyde dehydrogenases and their role in carcinogenesis’, Crit. Rev. Biochem. Mol. Biol. 1992, 27, 283–335.
Google Scholar
332 J. E. Patanella, J. S. Walsh, ‘Oxidation of carbovir, a carbocyclic nucleoside, by rat liver cytosolic enzymes’, Drug Metab. Dispos. 1992, 20, 912–919.
Google Scholar
333 W. Lenk, D. Löhr, J. Sonnenbichler, ‘Pharmacokinetics and biotransformation of diethylene glycol and ethylene glycol in the rat’, Xenobiotica 1989, 19, 961–979.
Google Scholar
334 E. D. Booth, O. Dofferhoff, P. J. Boogaard, W. P. Watson, ‘Comparison of the metabolism of ethylene glycol and glycolic acid in vitro by precision-cut tissue slices from female rat, rabbit and human liver’, Xenobiotica 2004, 34, 31–48.
Google Scholar
335 A. K. Sohlenius-Sternbeck, H. von Euler Chelpin, A. Orzechowski, M. M. Halldin, ‘Metabolism of sameridine to monocarboxylated products by hepatocytes isolated from the male rat’, Drug Metab. Dispos. 2000, 28, 695–700.
Google Scholar
336 J. J. R. Hermans, H. H. W. Thijssen, ‘Stereoselective acetonyl side chain reduction of warfarin and analogs’, Drug Metab. Dispos. 1992, 20, 268–274.
Google Scholar
337 S. J. Porter, A. A. Somogyi, J. M. White, ‘Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol’, Br. J. Clin. Pharmacol. 2000, 50, 465–471.
Google Scholar
338 U. Breyer-Pfaff, K. Nill, ‘Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol’, J. Pharm. Pharmacol. 2004, 56, 1601–1606.
Google Scholar
339 S. Yamano, F. Ichinose, T. Todaka, S. Toki, ‘Purification and characterization of two major forms of naloxone reductase from rabbit liver cytosol, new members of aldo-keto reductase superfamily’, Biol. Pharm. Bull. 1999, 22, 1038–1046.
Google Scholar
340 U. Breyer-Pfaff, H. J. Martin, M. Ernst, E. Maser, ‘Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat liver and by enzymes isolated from human liver’, Drug Metab. Dispos. 2004, 32, 915–922.
Google Scholar
341 H. J. Martin, U. Breyer-Pfaff, V. Wsol, S. Venz, S. Block, E. Maser, ‘Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics’, Drug Metab. Dispos. 2006, 34, 464–470;
Google Scholar
J. Dow, C. Berg, ‘Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs and humans’, Chirality 1995, 7, 342–348.
Google Scholar
342 B. Testa, ‘Some chemical and stereochemical aspects of diethylpropion metabolism in man’, Acta Pharm. Suec. 1973, 10, 441–454;
Google Scholar
M. Reist, L. H. Christiansen, P. Christoffersen, P. A. Carrupt, B. Testa, ‘Low configurational stability of amfepramone and cathinone: Mechanism and kinetics of chiral inversion’, Chirality 1995, 7, 469–473.
Google Scholar
343 T. M. Penning, ‘Dihydrodiol dehydrogenase and its role in polycyclic aromatic hydrocarbon metabolism’, Chem.-Biol. Interact. 1993, 89, 1–34.
Google Scholar
344 T. M. Penning, M. E. Burczynski, C. F. Hung, K. D. McCoull, N. T. Palackal, L. S. Tsuruda, ‘Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones’, Chem. Res. Toxicol. 1999, 12, 1–18.
Google Scholar
345 N. T. Palackal, S. H. Lee, R. G. Harvey, I. A. Blair, T. M. Penning, ‘Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells’, J. Biol. Chem. 2002, 277, 24799–24808.
Google Scholar
346 N. T. Palackal, M. E. Burczynski, R. G. Harvey, T. M. Penning, ‘The ubiquitous aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: potential role in polycyclic aromatic hydrocarbon activation’, Biochemistry 2001, 40, 10901–10910.
Google Scholar
347 T. M. Cho, R. L. Rose, E. Hodgson, ‘In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes’, Drug Metab. Dispos. 2006, 34, 176–183.
Google Scholar
348 K. Sugiyama, T. C. Lin Wang, J. T. Simpson, L. Rodriguez, P. F. Kador, S. Sato, ‘Aldose reductase catalyzes the oxidation of naphthalene-1,2-dihydrodiol for the formation of ortho-naphthoquinone’, Drug Metab. Dispos. 1999, 27, 60–67.
Google Scholar
349 W. Xue, D. Warshawsky, ‘Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review’, Toxicol. Appl. Pharmacol. 2005, 206, 73–93.
Google Scholar
350 T. M. Penning, S. T. Ohnishi, T. Ohnishi, R. G. Harvey, ‘Generation of reactive oxygen species during the enzymatic oxidation of polycyclic aromatic hydrocarbons trans-dihydrodiols catalyzed by dihydrodiol dehydrogenase’, Chem. Res. Toxicol. 1996, 9, 84–92.
Google Scholar
351 T. J. Monks, R. P. Hanzlik, G. M. Cohen, D. Ross, D. G. Graham, ‘Quinone chemistry and toxicity’, Toxicol. Appl. Pharmacol. 1992, 112, 2–16;
Google Scholar
J. L. Bolton, M. A. Trush, T. M. Penning, G. Dryherst, T. J. Monks, ‘Role of quinones in toxicology’, Chem. Res. Toxicol. 2000, 13, 135–160.
Google Scholar
352 K. D. McCoull, D. Rindgen, I. A. Blair, T. M. Penning, ‘Synthesis and characterization of polycyclic aromatic hydrocarbons o-quinone depurinating N7-guanine adducts’, Chem. Res. Toxicol. 1999, 12, 237–246.
Google Scholar
353 K. Seite, M. Murata, K. Hirakawa, Y. Deyashiki, S. Kawanishi, ‘Oxidative DNA damage induced by benz[a]anthracene dihydrodiols in the presence of dihydrodiol dehydrogenase’, Chem. Res. Toxicol. 2004, 17, 1445–1451.
Google Scholar
354 J. Jarabak, R. G. Harvey, ‘Studies on three reductases which have polycyclic aromatic hydrocarbon quinones as substrates’, Arch. Biochem. Biophys. 1993, 303, 394–401.
Google Scholar
355 G. D. Buffinton, K. Öllinger, A. Brunmark, E. Cadenas, ‘DT-Diaphorase-catalyzed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates. Effect of substituents on autoxidation rates’, Biochem. J. 1989, 257, 561–571.
Google Scholar
356 T. J. Monks, S. S. Lau, ‘Toxicology of quinone-thioethers’, Crit. Rev. Toxicol. 1992, 22, 243–270.
Google Scholar
357 P. Joseph, D. J. Long II, A. J. P. Klein-Szanto, A. K. Jaiswal, ‘Role of NAD(P)H : quinone oxidoreductase I (DT diaphorase) in protection against quinone toxicity’, Biochem. Pharmacol. 2000, 60, 207–214.
Google Scholar
358 R. Munday, ‘Activation and detoxification of naphthoquinones by NAD(P)H : quinone oxidoreductase’, Methods Enzymol. 2004, 382, 364–380.
Google Scholar
359 L. J. Chen, E. H. Lebetkin, L. T. Burka, ‘Metabolism and disposition of juglone in male F344 rats’, Xenobiotica 2005, 35, 1019–1034.
Google Scholar
360 R. J. Riley, P. Workman, ‘DT-Diaphorase and cancer chemotherapy’, Biochem. Pharmacol. 1992, 43, 1657–1669.
Google Scholar
361 S. M. Bailey, A. D. Lewis, R. J. Knox, L. H. Patterson, G. R. Fisher, P. Workman, ‘Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites’, Biochem. Pharmacol. 1998, 56, 613–621.
Google Scholar
362 G. R. Fisher, P. L. Gutierrez, M. A. Oldcorne, L. H. Patterson, ‘NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase)-mediated two-electron reduction of anthraquinone-based agents and generation of hydroxyl radicals’, Biochem. Pharmacol. 1992, 43, 575–585.
Google Scholar
363 M. AbuKhader, J. Heap, C. De Matteis, B. Kellam, S. W. Doughty, N. Minton, M. Paoli, ‘Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex’, J. Med. Chem. 2005, 48, 7714–7719.
Google Scholar
364 D. Siegel, H. Beall, C. Senekowitsch, M. Kasai, H. Arai, N. W. Gibson, D. Ross, ‘Bioreductive activation of mitomycin C by DT-diaphorase’, Biochemistry 1992, 31, 7879–7885.
Google Scholar
365 R. M. Phillips, M. A. Naylor, M. Jaffar, S. W. Doughty, S. A. Everett, A. G. Breen, G. A. Choudry, I. J. Stratford, ‘Bioreductive activation of a series of indolquinones by human DT-diaphorase: structure–activity relationships’, J. Med. Chem. 1999, 42, 4071–4080.
Google Scholar
366 P. M. Loadman, R. M. Phillips, L. E. Lim, M. C. Bibby, ‘Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-aziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice’, Biochem. Pharmacol. 2000, 59, 831–837.
Google Scholar
367 R. M. Phillips, M. Jaffar, D. J. Maitland, P. M. Loadman, S. D. Shnyder, G. Steabs, P. A. Cooper, A. Race, A. V. Patterson, I. J. Stratford, ‘Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs’, Biochem. Pharmacol. 2004, 68, 2107–2116.
Google Scholar

Citing Literature

Volume4, Issue3

March 2007

Pages 257-405

The Biochemistry of Drug Metabolism – An Introduction

Part 2. Redox Reactions and Their Enzymes

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The Biochemistry of Drug Metabolism – An Introduction

Part 2. Redox Reactions and Their Enzymes

Abstract

References

Citing Literature

References

Related

Information